Joseph H. Skalski, M.D.

The purpose of this study is to compare the gut bacterial and fungal microbiota profiles of patients with different asthma phenotypes (eosinophilic asthma and non-eosinophilic asthma).

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.

The purpose of this study is to describe the airway mycobiome in patients with bronchiectasis and to identify microbial signatures associated with eosinophilic inflammation, as well as disease severity and control.

The purpose of this study is to compare the gut bacterial and fungal microbiota profiles of patients with poorly-controlled asthma and patients with well-controlled asthma. 

The purpose of this study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of patient demographics, and patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height). T

Additionally to characterize real-world use patterns, safety, and long-term effectiveness of DUPIXENT® for asthmam and to assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® .